Oncoinvent reports continued progress in the ongoing Phase 2 trial in ovarian
cancer with a strong focus on advancing the program and maximizing recruitment.
Highlights for the first half of 2025:
Radspherin®
. Positive final data from Phase1/2a trial in colorectal cancer
patients
. Positive interim 18-months data from Phase1 trial in ovarian
cancer patients
. Positive read-out of safety lead-in cohort and opening of
randomized part of Phase 2 trial in ovarian cancer patients
. Regulatory approvals for additional sites for the randomized Phase
2 trial in ovarian cancer, with expected onboarding before end of 2025
Corporate
. Operating expenses reduced by 28% versus last year
. Merger with BerGenBio
. Fully guaranteed rights issue of NOKm 130
CEO Øystein Soug and CFO Tore Kvam will present the results for the first half
of 2025 at a webcast available at
https://channel.royalcast.com/landingpage/hegnarmedia/20250827_3/, Wednesday 27
August at 08:00 CEST. The presentation and Q&A will be held in English. A
recording of the webcast will be made available on our website shortly after the
presentation.
About Oncoinvent
Oncoinvent is a clinical-stage biotechnology company developing novel
radiopharmaceutical therapies against cancer. The lead product candidate,
Radspherin®, uses the alpha-emitting radionuclide radium-224, directly targeting
micro-metastases post-surgery, harnessing the benefits of modern
radiopharmaceuticals without the complexities of biological targeting.
Oncoinvent is investigating the safety and efficacy of Radspherin® in a clinical
development program in two indications. In addition to a recently finalized
phase 1/2a trial in colorectal cancer, Oncoinvent is running two trials in
ovarian cancer: one phase 1 trial and one randomized phase 2 trial in the US, UK
and Europe. Preliminary clinical efficacy data are highly encouraging, and no
serious toxicity or safety concerns have been reported to date. The Oncoinvent
team runs a state-of-the-art manufacturing facility to produce drug products for
clinical trials in Nydalen, Oslo. Oncoinvent is listed on the Euronext Growth
Oslo.
About Radspherin
Radspherin® is an investigational radiopharmaceutical designed for the local
treatment of cancer that has spread to body cavities. It consists of calcium
carbonate microparticles containing the radioactive material radium-224. The
mode of action is the decay of radium-224 emitting alpha-particles, a highly
potent form of ionizing radiation. Radspherin® is investigated in ongoing
clinical studies to treat peritoneal carcinomatoses from ovarian and colorectal
cancer and it is administered intraperitoneally after surgical resection with
removal of all macroscopic tumors.
Forward-Looking Statements
All statements other than statements of historical facts contained in this press
release are forward-looking statements and are not a representation that
Oncoinvent's plans, estimates, or expectations will be achieved. These forward
-looking statements represent Oncoinvent's expectations as of the date of this
press release, and Oncoinvent disclaims any obligation to update the forward
-looking statements. These forward-looking statements are subject to known and
unknown risks and uncertainties that may cause actual results to differ
materially, including with respect to whether the results of clinical or other
studies will support the use of our product offerings, the impact of results of
such studies, our expectations of the reliability, accuracy and performance of
our tests, or of the benefits of our tests and product offerings to patients,
providers and payers.
For further information, please contact:
Øystein Soug, Chief Executive Officer
Email: soug@oncoinvent.com
Tore Kvam, Chief Financial Officer
Email: kvam@oncoinvent.com